Acetyl Hexapeptide-3 is a six-amino-acid synthetic peptide related to the N-terminal region of SNAP-25, a protein involved in SNARE-mediated membrane fusion and regulated exocytosis. Its defined sequence, N-terminal acetylation, and C-terminal amidation make it useful for studying short peptide–protein interactions, vesicle-associated signaling, formulation behavior, and skin-related peptide biology.

The peptide is also widely referred to as Acetyl Hexapeptide-8. Because both names appear in scientific and commercial literature, sequence identity is more informative than nomenclature alone when comparing research materials.

Product Information

Sequence and Terminal Design

The research sequence is:

Ac-EEMQRR-NH₂

Both termini are chemically modified. The N-terminal acetyl group and C-terminal amide are therefore part of the defined molecular identity and should be retained when researchers compare the peptide with analogs, truncated sequences, or modified variants.

The molecule contains acidic and basic residues within a compact six-residue sequence. This combination contributes to a relatively polar peptide profile and makes assay environment, concentration, and delivery strategy relevant to experimental interpretation.

SNAP-25 and SNARE Research Context

SNAP-25 participates in the SNARE machinery that supports vesicle docking and membrane fusion. Acetyl Hexapeptide-3 was developed from a SNAP-25-related sequence and has been investigated for its ability to interfere with productive SNARE-complex assembly in experimental systems.

This mechanism is distinct from enzymatic cleavage of SNAP-25 by botulinum neurotoxins. Acetyl Hexapeptide-3 is therefore better treated as a small synthetic research peptide used to investigate SNARE-associated processes, rather than as a molecular substitute for botulinum toxin.

For laboratories studying related sequence variants or terminal modifications, our Custom Peptide Synthesis capabilities support project-specific peptide preparation.

Delivery and Experimental Interpretation

One important consideration with Acetyl Hexapeptide-3 is that biochemical activity and effective delivery are separate experimental questions.

Its polar character can limit passive transport across lipid-rich biological barriers. Results obtained in cell-free systems, cultured cells, reconstructed tissue models, or formulated delivery systems should therefore be interpreted according to the exposure conditions used in each experiment.

We consider peptide concentration, solvent composition, formulation, incubation time, and biological model particularly important when comparing datasets from different studies.

Research Applications

Acetyl Hexapeptide-3 can be used in studies involving SNARE-associated signaling, regulated exocytosis, short peptide–protein interactions, peptide delivery, skin-related cellular models, and structure–activity relationships.

It also provides a practical scaffold for comparing acetylation, amidation, residue substitution, labeling, and other sequence modifications without introducing the synthetic complexity associated with much longer peptides.

Synthetic and Quality Control Considerations

Although Acetyl Hexapeptide-3 is short, correct terminal chemistry remains essential. A peptide with the correct amino-acid sequence but missing acetylation or amidation represents a different molecular form.

Analytical HPLC can be used to assess chromatographic purity, while mass spectrometry supports confirmation of the expected molecular mass. Researchers can review our Peptide Quality Control capabilities when planning analytical requirements.

For quantitative or cell-based work, purity should be selected according to assay sensitivity rather than peptide length alone.

Purity and Experimental Planning

Different workflows may require different specifications. Exploratory screening may not require the same purity as quantitative biochemical or cell-based assays.

Researchers can refer to our Recommended Peptide Purity guidance when selecting an appropriate specification.

We recommend confirming the sequence, N-terminal acetylation, C-terminal amidation, molecular mass, and requested purity before initiating comparative experiments.

Frequently Asked Questions

What is Acetyl Hexapeptide-3?

Acetyl Hexapeptide-3 is a six-residue synthetic peptide with the sequence Ac-EEMQRR-NH₂. It is primarily studied in relation to SNAP-25, SNARE-complex biology, exocytosis, and peptide delivery.

Is Acetyl Hexapeptide-3 the same as Acetyl Hexapeptide-8?

The sequence Ac-EEMQRR-NH₂ is commonly described under both names. Researchers should use the exact sequence and terminal modifications to confirm molecular identity.

Does Acetyl Hexapeptide-3 work like botulinum toxin?

They are not the same type of molecule and do not act through an identical mechanism. Botulinum neurotoxins enzymatically cleave components of the neurotransmitter-release machinery, whereas Acetyl Hexapeptide-3 has been investigated as a short peptide that interferes with SNARE-associated interactions.

Why are the terminal modifications important?

N-terminal acetylation and C-terminal amidation are part of the specified peptide structure. Removing either modification changes molecular mass, charge characteristics, and potentially experimental behavior.

Can Acetyl Hexapeptide-3 analogs be synthesized?

Yes. Sequence substitutions, terminal modifications, purity levels, quantities, and selected labeling strategies can be evaluated as custom peptide projects.

Research Use Only.